Literature DB >> 21656338

High doses of oxycodone-naloxone combination may provide poor analgesia.

Sebastiano Mercadante1, Patrizia Ferrera, Claudio Adile.   

Abstract

Several studies have shown that an oxycodone/naloxone combination (ratio 2:1) provides analgesia and less constipation in non-cancer patients receiving relatively low doses of this formulation. A case report of a cancer patient who was receiving increasing doses of oxycodone with an unexpected declining analgesia is presented. The substitution with the same doses (240 mg/day) of regular controlled-release oxycodone was effective in regaining adequate analgesia.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21656338     DOI： 10.1007/s00520-011-1205-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  13 in total

1.  Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

Authors:  Colette M Reid; Richard M Martin; Jonathan A C Sterne; Andrew N Davies; Geoffrey W Hanks
Journal:  Arch Intern Med       Date:  2006-04-24

2.  The use of high doses of oxycodone in an acute palliative care unit.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Fabrizio David; Alessandra Casuccio
Journal:  Am J Hosp Palliat Care       Date:  2010-09-08       Impact factor: 2.500

Review 3.  Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.

Authors:  Stefan Mueller-Lissner
Journal:  Adv Ther       Date:  2010-08-11       Impact factor: 3.845

Review 4.  Role of oxycodone and oxycodone/naloxone in cancer pain management.

Authors:  Wojciech Leppert
Journal:  Pharmacol Rep       Date:  2010 Jul-Aug       Impact factor: 3.024

5.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

6.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

7.  A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Authors:  Winfried Meissner; Petra Leyendecker; Stefan Mueller-Lissner; Joachim Nadstawek; Michael Hopp; Christian Ruckes; Stefan Wirz; Wolfgang Fleischer; Karen Reimer
Journal:  Eur J Pain       Date:  2008-08-31       Impact factor: 3.931

8.  Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Authors:  Kevin Smith; Michael Hopp; Gill Mundin; Petra Leyendecker; Paul Bailey; Birgit Grothe; Reiner Uhl; Karen Reimer
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

Review 9.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Morphine and alternative opioids in cancer pain: the EAPC recommendations.

Authors:  G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640
View more
  13 in total

1.  Clarifications on oxycodone-naloxone combination in cancer pain management.

Authors:  Sebastiano Mercadante
Journal:  Support Care Cancer       Date:  2012-04-14       Impact factor: 3.603

2.  Some concerns about the article: "High doses of oxycodone-naloxone combination may provide poor analgesia.".

Authors:  Christian Compagnone; Fernanda Tagliaferri; Andrea Ramelli
Journal:  Support Care Cancer       Date:  2011-12-28       Impact factor: 3.603

Review 3.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

4.  Complications with oxycodone and naloxone.

Authors:  Alicia Ward; Michaela Del Campo; Kathy Hauser
Journal:  Aust Prescr       Date:  2017-08-01

5.  High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.

Authors:  Francesco Amato; Silvia Ceniti; Sergio Mameli; Giovanni M Pisanu; Renato Vellucci; Vincenzo Palmieri; Leonardo Consoletti; Dorotea Magaldi; Paolo Notaro; Claudio Marcassa
Journal:  Support Care Cancer       Date:  2017-05-03       Impact factor: 3.603

Review 6.  Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

Authors:  Wojciech Leppert
Journal:  Drug Des Devel Ther       Date:  2015-04-16       Impact factor: 4.162

7.  Use of oxycodone in pain management.

Authors:  Mohammad Moradi; Sara Esmaeili; Saeed Shoar; Saeid Safari
Journal:  Anesth Pain Med       Date:  2012-04-01

Review 8.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

9.  The place of oxycodone/naloxone in chronic pain management.

Authors:  Wojciech Leppert
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

10.  The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.

Authors:  Wojciech Leppert
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.